Inactief instrument

Andere talen JHL Biotech, Inc.

Aandelen

6540

KYG7863U1076

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Bora Pharmaceutical Laboratories Inc. acquired CDMO Assets of JHL Biotech, Inc. for $100 million.	10-05-22
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar	18-05-20
JHL Biotech, Inc. Announces First Patient Randomized in the Phase Iii Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma	27-12-18
JHL Biotech, Inc. Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer	15-10-18
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer	10-08-18
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar	09-07-18
Jhl Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma	05-07-18
JHL Biotech, Inc. Appoints Ellis Chu as Chief Financial Officer	13-06-18
JHL Biotech, Inc. announced that it has received $106 million in funding from a group of investors	15-05-18
JHL Biotech Seeks Financing	30-03-18
JHL Biotech, Inc. Announces European Authority, Bulgarian Drug Agency Approves Phase I Clinical Trial Application	22-02-18
JHL Biotech, Inc.(GTSM:6540) dropped from S&P Global BMI Index	12-02-18
JHL Biotech, Inc.'s Board intends to launch an Equity Buyback.	05-02-18
JHL Biotech, Inc. announced that it expects to receive $150 million in funding	16-01-18
JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis	20-12-17
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers	20-12-17
JHL Biotech Inc Announces Its Clinical Trial Application for Use of JHL1101 in Phase 1 and Phase 3 Clinical Trials	05-04-17
JHL Doses First Patient In JHL1101 Phase I European Trial	29-03-17
Sanofi Enters into Strategic Biologics Alliance with JHL Biotech in China	05-12-16
JHL Biotech, Inc. announced that it expects to receive TWD 2.55 billion in funding from Sanofi	05-12-16

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen JHL Biotech, Inc.

Aandelen

6540

KYG7863U1076

Andere talen

Filters